<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01367873</url>
  </required_header>
  <id_info>
    <org_study_id>VIA-3196-01</org_study_id>
    <nct_id>NCT01367873</nct_id>
  </id_info>
  <brief_title>Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Madrigal Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Madrigal Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, double-blind, placebo-controlled, ascending single-dose
      study of VIA-3196 to evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196
      in Healthy Subjects. Study dosing is organized into cohorts corresponding to escalating doses
      of VIA-3196 or matching placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events as a measure of safety and tolerability of VIA-3196</measure>
    <time_frame>up to 12 days</time_frame>
    <description>Evaluation will start from predose (Day -1) until the follow-up visit (Day 7 to 11)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of VIA-3196</measure>
    <time_frame>0 to 72 hours</time_frame>
    <description>Assessed with and without food</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Drug Safety</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VIA-3196</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple, single-dose, ascending dosing groups (cohorts) will be evaluated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIA-3196 with Food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second, single dose administered after a standard high-fat breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with Food</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral, matching number of placebo capsule(s) with active arm</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Placebo with Food</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIA-3196</intervention_name>
    <description>Oral, capsule(s)</description>
    <arm_group_label>VIA-3196</arm_group_label>
    <arm_group_label>VIA-3196 with Food</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject must be willing and able to provide written informed consent.

          -  Healthy, non-smoking, males and females between the ages of 18 and 55 years of age
             (inclusive).

          -  If female, the subject is of non-child bearing potential (i.e., surgically [bilateral
             oophorectomy, hysterectomy, or tubal ligation] or naturally sterile [&gt;12 consecutive
             months without menses]). Verify by FSH at screening as appropriate.

          -  Body weight &gt; 50 kg and BMI between 18 and 30 kg/m2 (inclusive).

          -  LDL cholesterol &gt; 85 mg/dL.

          -  No clinically significant abnormal findings on blood pressure, heart rate, physical
             examination, clinical laboratory tests or 12-lead ECG.

        Key Exclusion Criteria:

          -  History of thyroid disorder or abnormal thyroid function tests at screening. Repeat
             testing is allowed at the discretion of the Investigator.

          -  History of unexplained syncope.

          -  History of hepatobiliary disease; or AST, ALT or direct bilirubin greater than the
             upper limit of reference range at screening.

          -  Positive screening test for HIV antibody, Hepatitis B surface antigen or Hepatitis C
             antibody.

          -  Abnormal screening ECG: including machine-read QTc &gt;450 msec, QRS &gt;110 msec,
             intermittent bundle branch block, frequent premature atrial or premature ventricular
             contractions, or any rhythm other than normal sinus rhythm which is interpreted by the
             Investigator to be clinically significant.

          -  History of sensitivity to a similar study drug (e.g., Karo Bio KB2115 or Metabasis
             MB7811), or a history of important drug or other allergy (except for untreated,
             asymptomatic seasonal allergies at time of dosing).

          -  Sensitivity to thyroid medication.

          -  History of asthma, or intolerance to beta-blockers.

          -  Use of acetaminophen within 7 days before dosing and throughout the study.

          -  History of regular use of tobacco or nicotine containing products within the past 6
             months.

          -  Positive urine drug screen or alcohol test at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Taub, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Madrigal Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2011</study_first_submitted>
  <study_first_submitted_qc>June 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2011</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

